Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Nephrology
Published in: Journal of Nephrology 1/2016

Open Access 01-02-2016 | Review

Role of complement in IgA nephropathy

Authors: Mohamed R. Daha, Cees van Kooten

Published in: Journal of Nephrology | Issue 1/2016

Login to get access

Abstract

Immunoglobulin A nephropathy (IgAN) is characterized by the deposition of IgA in the mesangium of glomeruli. This mesangial IgA has been found to consist mainly of polymeric IgA1 which drives the activation of the mesangial cells and results in excessive production of several inflammatory mediators. The activation of mesangial cells is amplified by the ability of IgA to activate the complement system, originally thought to occur mainly via the alternative pathway of complement. However more recent studies indicate that lectin pathway involvement has a strong association with progression of renal disease. In this review we summarize the contribution of complement to the IgA- mediated inflammatory process.
Literature
1.
Garred P, Honore C, Ma YJ, Munthe-Fog L, Hummelshoj T (2009) MBL2, FCN1, FCN2 and FCN3-The genes behind the initiation of the lectin pathway of complement. Mol Immunol 46(14):2737–2744PubMedCrossRef
2.
3.
Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT (1996) C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271:348–350PubMedCrossRef
4.
Kemper C, Atkinson JP, Hourcade DE (2010) Properdin: emerging roles of a pattern-recognition molecule. Annu Rev Immunol 28:131–155PubMedCrossRef
5.
Nauta AJ, Daha MR, van Kooten C, Roos A (2003) Recognition and clearance of apoptotic cells: a role for complement and pentraxins. Trends Immunol 24:148–154PubMedCrossRef
6.
Floege J, Moura IC, Daha MR (2014) New insights into the pathogenesis of IgA nephropathy. Semin Immunopathol 36(4):431–442PubMedCrossRef
7.
Endo M, Ohi H, Ohsawa I, Fujita T, Matsushita M, Fujita T (1998) Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant 13(8):1984–1990PubMedCrossRef
8.
Maeng YI, Kim MK, Park JB, Cho CH, Oh HK, Sung WJ, Park KK (2013) Glomerular and tubular C4d depositions in IgA nephropathy: relations with histopathology and with albuminuria. Int J Clin Exp Pathol 6(5):904–910PubMedPubMedCentral
9.
Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N, van Gijlswijk-Janssen DJ, Stahl GL, Matsushita M, Fujita T, van Kooten C, Daha MR (2006) Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 17:1724–1734PubMedCrossRef
10.
Faria B, Henriques C, Matos AC, Daha MR, Pestana M, Seelen M (2015) Combined C4d and CD3 immunostaining predicts immunoglobulin (Ig)A nephropathy progression. Clin Exp Immunol 179(2):354–361PubMedCrossRef
11.
Espinosa M, Ortega R, Sanchez M, Segarra A, Salcedo MT, Gonzalez F, Camacho R, Valdivia MA, Cabrera R, Lopez K, Pinedo F, Gutierrez E, Valera A, Leon M, Cobo MA, Rodriguez R, Ballarin J, Arce Y, Garcia B, Munoz MD, Praga M (2014) Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol 9(5):897–904PubMedPubMedCentralCrossRef
12.
Mestecky J, Raska M, Julian BA, Gharavi AG, Renfrow MB, Moldoveanu Z, Novak L, Matousovic K, Novak J (2013) IgA nephropathy: molecular mechanisms of the disease. Annu Rev Pathol 8:217–240PubMedCrossRef
13.
Oortwijn BD, Rastaldi MP, Roos A, Mattinzoli D, Daha MR, van Kooten C (2007) Demonstration of secretory IgA in kidneys of patients with IgA nephropathy. Nephrol Dial Transplant 22:3191–3195PubMedCrossRef
14.
15.
Yu XQ, Li M, Zhang H, Low HQ, Wei X, Wang JQ, Sun LD, Sim KS, Li Y, Foo JN, Wang W, Li ZJ, Yin XY, Tang XQ, Fan L, Chen J, Li RS, Wan JX, Liu ZS, Lou TQ, Zhu L, Huang XJ, Zhang XJ, Liu ZH, Liu JJ (2011) A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet 44(2):178–182PubMedCrossRef
16.
Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, Sanna-Cherchi S, Men CJ, Julian BA, Wyatt RJ, Novak J, He JC, Wang H, Lv J, Zhu L, Wang W, Wang Z, Yasuno K, Gunel M, Mane S, Umlauf S, Tikhonova I, Beerman I, Savoldi S, Magistroni R, Ghiggeri GM, Bodria M, Lugani F, Ravani P, Ponticelli C, Allegri L, Boscutti G, Frasca G, Amore A, Peruzzi L, Coppo R, Izzi C, Viola BF, Prati E, Salvadori M, Mignani R, Gesualdo L, Bertinetto F, Mesiano P, Amoroso A, Scolari F, Chen N, Zhang H, Lifton RP (2011) Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 43(4):321–327PubMedPubMedCentralCrossRef
17.
Feehally J, Farrall M, Boland A, Gale DP, Gut I, Heath S, Kumar A, Peden JF, Maxwell PH, Morris DL, Padmanabhan S, Vyse TJ, Zawadzka A, Rees AJ, Lathrop M, Ratcliffe PJ (2010) HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol 21(10):1791–1797PubMedPubMedCentralCrossRef
18.
Jozsi M, Tortajada A, Uzonyi B, Goicoechea de JE, Rodriguez de CS (2015) Factor H-related proteins determine complement-activating surfaces. Trends Immunol 36(6):374–384
19.
Zhu L, Zhai YL, Wang FM, Hou P, Lv JC, Xu DM, Shi SF, Liu LJ, Yu F, Zhao MH, Novak J, Gharavi AG, Zhang H (2015) Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy. J Am Soc Nephrol 26(5):1195–1204PubMedCrossRef
20.
Onda K, Ohsawa I, Ohi H, Tamano M, Mano S, Wakabayashi M, Toki A, Horikoshi S, Fujita T, Tomino Y (2011) Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function. BMC Nephrol 12:64–122PubMedPubMedCentralCrossRef
21.
Rosenblad T, Rebetz J, Johansson M, Bekassy Z, Sartz L, Karpman D (2014) Eculizumab treatment for rescue of renal function in IgA nephropathy. Pediatr Nephrol 29(11):2225–2228PubMedCrossRef
Metadata
Title
Role of complement in IgA nephropathy
Authors
Mohamed R. Daha
Cees van Kooten
Publication date
01-02-2016
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 1/2016
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-015-0245-6

Other articles of this Issue 1/2016

Journal of Nephrology 1/2016 Go to the issue

Original Article

Use of iliac vein tunneled cuffed catheters in elderly hemodialysis patients: a single-center retrospective study

Original Article

Heritability of dietary traits that contribute to nephrolithiasis in a cohort of adult sibships

Original Article

Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low

Original Article

Serum biomarkers in uncontrolled no heart-beating donors may identify kidneys that will never work after transplantation

Original Article

Association of advanced age with concentrations of uraemic toxins in CKD

Original Article

Identifying acute kidney injury in the community—a novel informatics approach
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits